Cargando…

Different Serotonergic Expression in Nevomelanocytic Tumors

The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression. Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors. For this purpose, paraffin-embedded biopsies of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Naimi-Akbar, Clara, Ritter, Markus, Demel, Sasika, El-Nour, Husameldin, Hedblad, Mari-Anne, Azmitia, Efrain C., Nordlind, Klas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835124/
https://www.ncbi.nlm.nih.gov/pubmed/24281111
http://dx.doi.org/10.3390/cancers2021166
_version_ 1782292105228451840
author Naimi-Akbar, Clara
Ritter, Markus
Demel, Sasika
El-Nour, Husameldin
Hedblad, Mari-Anne
Azmitia, Efrain C.
Nordlind, Klas
author_facet Naimi-Akbar, Clara
Ritter, Markus
Demel, Sasika
El-Nour, Husameldin
Hedblad, Mari-Anne
Azmitia, Efrain C.
Nordlind, Klas
author_sort Naimi-Akbar, Clara
collection PubMed
description The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression. Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors. For this purpose, paraffin-embedded biopsies of superficial spreading malignant melanoma (SSM), dysplastic compound nevi (DN) and benign compound nevi (BCN) were characterized with regard to their expression of 5-HT, the 5-HT1A and 5-HT2A receptors, and the serotonin transporter protein (SERT), by immunohistochemical analysis. Melanocytes in the region surrounding the tumor were found to express both the 5-HT1A and 5-HT2A receptors. Tumor cells that immunostained positively for the different serotonergic markers were observed in the suprabasal epidermis of DN tissue and, to an even greater extent, in the case of SSM. Furthermore, some of these latter cells expressed both 5-HT1AR and 5-HT2AR. The level of expression of 5-HT1AR at the junctional area was lower for SSM than for DN or BCN. As the degree of atypia increased, the intensity of tumor cell staining in the dermis for 5-HT1AR and SERT declined. Vessel immunoreactivity for 5-HT2A was more intense in SSM than in BCN tissue. Round-to-dendritic cells that expressed both SERT and 5-HT1AR were seen to infiltrate into the dermal region of the tumor, this infiltration being more evident in the case of DN and SSM. These latter cells were also tryptase-positive, indicating that they are mast cells. Thus, alterations in serotonergic system may be involved in nevomelanocytic tumors and mast cells may play an important role in this connection.
format Online
Article
Text
id pubmed-3835124
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-38351242013-11-21 Different Serotonergic Expression in Nevomelanocytic Tumors Naimi-Akbar, Clara Ritter, Markus Demel, Sasika El-Nour, Husameldin Hedblad, Mari-Anne Azmitia, Efrain C. Nordlind, Klas Cancers (Basel) Article The neuromediator serotonin (5-hydroxytryptamine; 5-HT) has been proposed to play a role in tumor progression. Thus, the aim of the present investigation was to determine whether alterations in the serotonergic system occur in nevomelanocytic tumors. For this purpose, paraffin-embedded biopsies of superficial spreading malignant melanoma (SSM), dysplastic compound nevi (DN) and benign compound nevi (BCN) were characterized with regard to their expression of 5-HT, the 5-HT1A and 5-HT2A receptors, and the serotonin transporter protein (SERT), by immunohistochemical analysis. Melanocytes in the region surrounding the tumor were found to express both the 5-HT1A and 5-HT2A receptors. Tumor cells that immunostained positively for the different serotonergic markers were observed in the suprabasal epidermis of DN tissue and, to an even greater extent, in the case of SSM. Furthermore, some of these latter cells expressed both 5-HT1AR and 5-HT2AR. The level of expression of 5-HT1AR at the junctional area was lower for SSM than for DN or BCN. As the degree of atypia increased, the intensity of tumor cell staining in the dermis for 5-HT1AR and SERT declined. Vessel immunoreactivity for 5-HT2A was more intense in SSM than in BCN tissue. Round-to-dendritic cells that expressed both SERT and 5-HT1AR were seen to infiltrate into the dermal region of the tumor, this infiltration being more evident in the case of DN and SSM. These latter cells were also tryptase-positive, indicating that they are mast cells. Thus, alterations in serotonergic system may be involved in nevomelanocytic tumors and mast cells may play an important role in this connection. Molecular Diversity Preservation International (MDPI) 2010-06-07 /pmc/articles/PMC3835124/ /pubmed/24281111 http://dx.doi.org/10.3390/cancers2021166 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Naimi-Akbar, Clara
Ritter, Markus
Demel, Sasika
El-Nour, Husameldin
Hedblad, Mari-Anne
Azmitia, Efrain C.
Nordlind, Klas
Different Serotonergic Expression in Nevomelanocytic Tumors
title Different Serotonergic Expression in Nevomelanocytic Tumors
title_full Different Serotonergic Expression in Nevomelanocytic Tumors
title_fullStr Different Serotonergic Expression in Nevomelanocytic Tumors
title_full_unstemmed Different Serotonergic Expression in Nevomelanocytic Tumors
title_short Different Serotonergic Expression in Nevomelanocytic Tumors
title_sort different serotonergic expression in nevomelanocytic tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835124/
https://www.ncbi.nlm.nih.gov/pubmed/24281111
http://dx.doi.org/10.3390/cancers2021166
work_keys_str_mv AT naimiakbarclara differentserotonergicexpressioninnevomelanocytictumors
AT rittermarkus differentserotonergicexpressioninnevomelanocytictumors
AT demelsasika differentserotonergicexpressioninnevomelanocytictumors
AT elnourhusameldin differentserotonergicexpressioninnevomelanocytictumors
AT hedbladmarianne differentserotonergicexpressioninnevomelanocytictumors
AT azmitiaefrainc differentserotonergicexpressioninnevomelanocytictumors
AT nordlindklas differentserotonergicexpressioninnevomelanocytictumors